• Essential hypertension
  • Kidney lesion in hypertension and achrestic diabetes mellitus(consisting of complex therapy)

Posology and method of administration

The usual recommended and supporting dose of Avalide is 150 mg once a day. The drug can be taken regardless of meals. The pills should be swallowed whole with water. If it is necessary, the dose can be increased to 300 mg 1 time per day or prescribe combine antihypertensive therapy.
Patients with non-insulin dependent diabetes mellitus and arterial hypertension drug is started to take at a dose of 150 mg once a day and then increase the dose to 300 mg once a day, which is preferred maintenance dose in renal disease. Persons older than 75 years should start therapy with 75 mg.

  • Violation of renal function.
  • Patients with impaired renal function shouldn’t change doses.
  • Patients on hemodialysis should start therapy with 75 mg.
  • Inadequate intra-vascular blood volume.
  • Before you start the application of Avalide you must bridge deficit of liquid and / or sodium.
  • Disturbances of hepatic function.
  • Patients with mild or moderate hepatic function violation correction shouldn’t correct the dose.

Side effects

  • Hypersensitivity reactions, such as skin sprinkle, urticaria, angioedema
  • Hyperkalemia
  • Headache, dizziness
  • Noise in ears
  • Nausea and / or vomiting
  • Dysgeusia
  • Weakness
  • A significant increase of creatine kinase levels
  • Orthostatic dizziness
  • Orthostatic hypotension
  • Hepatitis, change of hepatic function
  • Arthralgia, myalgia (in some cases in combination of increased levels of creatine kinase (CK)), muscle cramps
  • Renal function violation including cases of acute renal deficiency in patients with an increased risk
  • Leukocyte vasculitis


  • Heart hurry
  • Hot flushes
  • Cough
  • Diarrhea, dyspepsia, heartburn
  • Sexual dysfunction
  • Chest pain
  • Treatment should be discontinued with the development of severe adverse effects


  • Hypersensitivity to the active substance or helpful components of the drug
  • Pregnancy and lactation
  • Child and adolescence to 18 years
  • Primary hyperaldosteronism